recent
year
demand
new
antivir
strategi
increas
markedli
mani
contribut
factor
increas
demand
includ
everincreas
preval
chronic
viral
infect
hiv
hepat
b
c
emerg
new
virus
sar
coronaviru
potenti
danger
haemorrhag
fever
virus
erad
virus
variola
viru
use
bioterrorist
weapon
also
increas
profil
antivir
drug
discoveri
viru
infect
antivir
therapi
need
compound
avail
develop
treatment
infect
describ
zidovudin
azt
didanosin
ddi
zalcitabin
ddc
stavudin
lamivudin
abacavir
abc
emtricitabin
ftc
nucleotid
revers
transcriptas
inhibitor
ntrti
tenofovir
disoproxil
bi
isopropoxycarbonyloxymethyl
ester
r
adenin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
delavirdin
efavirenz
proteas
inhibitor
pi
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
atazanavir
fusion
inhibitor
fi
enfuvirtid
pentafusid
hbv
infect
lamivudin
adefovir
dipivoxil
bi
pivaloyloxymethyl
ester
adenin
hsv
vzv
infect
acyclovir
oral
prodrug
valaciclovir
penciclovir
oral
prodrug
famciclovir
idoxuridin
idu
trifluridin
tft
brivudin
e
bvdu
ganciclovir
oral
prodrug
valganciclovir
foscarnet
phosphonoform
acid
pfa
trisodium
salt
cidofovir
cytosin
hpmpc
fomivirsen
antisens
phosphorothio
oligonucleotid
interest
develop
new
antivir
compound
mainli
fuell
two
consider
requir
specif
antivir
drug
viru
infect
concern
link
could
reason
expect
viru
infect
would
control
use
antivir
drug
antivir
drug
avail
treat
prevent
viru
infect
concern
antivir
strategi
could
pursu
meet
demand
purpos
articl
examin
differ
viru
infect
approach
therapeut
viewpointnot
viru
infect
familiar
also
new
old
viru
infect
could
emerg
reemerg
respect
basic
strategi
use
design
antivir
drug
describ
previous
evalu
use
potenti
use
control
viru
infect
antivir
drug
formal
licens
medic
use
list
box
chemic
structur
compound
discuss
articl
shown
fig
remain
compound
discuss
shown
onlin
supplementari
inform
figur
viral
andor
cellular
target
antivir
agent
potenti
antivir
agent
present
tabl
parvoviru
pathogen
human
respons
socal
fifth
diseas
erythema
infectiosum
children
although
complic
arthriti
aplast
crisi
reticulocytopoenia
myocard
hydrop
fetali
pregnanc
occur
infect
viru
seriou
attempt
made
develop
either
prevent
therapeut
measur
diseas
question
whether
effort
made
develop
vaccin
cure
diseas
remain
open
debat
polyomavirus
jc
bk
virus
associ
thought
respons
progress
multifoc
leukoencephalopathi
pml
haemorrhag
cystiti
respect
patient
aid
sever
anecdot
case
report
indic
cidofovir
cytosin
hpmpc
effect
treatment
pml
aid
patient
given
dosag
recommend
treatment
human
cytomegaloviru
hcmv
retin
aid
patient
intraven
mg
kg
week
week
mg
kg
everi
week
concomit
probenecid
administr
activ
cidofovir
primat
murin
polyomavirus
demonstr
cell
cultur
vitro
far
antivir
drug
proven
effect
polyomaviru
infect
adenoviru
infect
immunocompet
individu
gener
selflimit
neither
prevent
therapeut
measur
vaccin
antivir
therapi
use
howev
allogen
haematopoiet
stemcel
transplant
hsct
recipi
adenoviru
infect
sever
patient
accord
anecdot
report
cidofovir
shown
effect
suppress
adenoviru
infect
wherea
ribavirin
vidarabin
present
cidofovir
seem
antivir
drug
could
success
use
treat
adenoviru
infect
particularli
hsct
recipi
includ
herp
simplex
viru
type
varicellazost
viru
vzv
caus
primari
infect
exampl
caus
gingivostomat
enceph
eczema
herpeticum
caus
genit
neonat
herp
vzv
caus
varicella
chickenpox
recurr
infect
exampl
caus
herp
labiali
herpet
kerat
caus
genit
herp
vzv
caus
herp
zoster
virus
also
caus
sever
dissemin
progress
mucocutan
infect
immunosuppress
patient
adequ
treatment
avail
infect
includ
acyclovir
oral
prodrug
sever
clinic
manifest
human
papillomaviru
hpv
infect
includ
verruca
vulgari
plantar
wart
hypopharyng
oesophag
laryng
respiratori
papillomatosi
genit
wart
condylomata
acuminata
cervic
intraepitheli
neoplasia
cin
develop
cervic
carcinoma
vulvar
intraepitheli
neoplasia
vin
penil
intraepitheli
neoplasia
pin
perian
intraepitheli
neoplasia
pain
inject
intralesion
appli
topic
gel
cream
cidofovir
prove
highli
efficaci
caus
regress
mani
hpvassoci
lesion
includ
laryng
papilloma
anogenit
wart
recurr
recurr
respond
promptli
anoth
cours
cidofovir
therapi
inhibitori
effect
cidofovir
prolifer
hpvinfect
cell
could
attribut
induct
apoptosi
cell
evid
cidofovir
restor
function
hpvassoci
cancer
two
antivir
agent
specif
hpv
infect
acycl
nucleosid
phosphon
analogu
pmeg
guanin
cprpmedap
n
select
inhibit
cell
organotyp
cocultur
primari
normal
human
keratinocyt
cervic
carcinoma
cell
host
situat
infect
treat
foscarnet
pyrophosph
analogu
acycl
nucleosid
phosphon
cidofovir
neither
depend
hsv
vzv
tk
antivir
action
fig
also
depend
activ
viral
tk
specif
vzvencod
tk
bicycl
furo
pyrimidin
nucleosid
analogu
bcna
cf
cf
cf
cf
compound
inhibit
vzv
replic
subnanomolar
concentr
even
greater
concentr
toxic
host
cell
unlik
classic
antivzv
compound
bcna
select
vzv
therefor
inact
alkyl
phenyl
side
chain
furanyl
ring
bcna
import
determin
specif
compound
valaciclovir
penciclovir
oral
prodrug
famciclovir
brivudin
bvdu
bvdu
licens
sever
european
countri
treatment
herp
zoster
acyclovir
penciclovir
acycl
nucleosid
analogu
addit
carbocycl
guanosin
analogu
cyclohexenylguanin
methylenecyclopropan
analogu
nucleosid
synguanol
accredit
potent
activ
vzv
methylenecyclopropan
analogu
also
prove
effect
hepat
b
viru
hbv
acycl
nucleosid
analogu
requir
phosphoryl
virusencod
thymidin
kinas
tk
exert
antivir
activ
fig
inhibit
tkdefici
hsv
vzv
strain
occasion
aris
particularli
immunocompromis
cidofovir
also
administ
intraven
albeit
weekli
everi
week
nephrotox
doselimit
factor
cidofovir
foscarnet
wherea
bonemarrow
suppress
result
granulocytopoenia
thrombocytopoenia
common
toxic
side
effect
seen
ganciclovir
taken
togeth
consider
justifi
search
new
antihcmv
agent
less
toxic
andor
effect
possibl
lead
compound
recent
shown
potent
vitro
activ
wide
rang
hcmv
refer
strain
clinic
isol
includ
acquir
resist
ganciclovir
foscarnet
cidofovir
target
step
viral
replic
cycl
dna
polymeras
step
probabl
coincid
immediateearli
antigen
express
nonnucleosid
carboxamid
interact
dna
polymeras
compound
inhibit
cellular
dna
polymeras
mitochondri
dna
polymeras
virus
resist
compound
found
singl
amino
acid
chang
valin
alanin
within
conserv
domain
iii
dna
polymeras
valin
residu
conserv
dna
polymeras
six
eight
human
herpesvirus
seem
crucial
role
observ
antiherpesviru
effect
compound
dna
polymeras
contain
alanin
posit
accordingli
inhibit
hcmv
terminas
compris
gene
product
target
chemotherapeut
intervent
togeth
gene
product
cleav
viral
highmolecularweight
dna
concatam
unitlength
genom
packag
monomer
genom
viral
procapsid
intervent
stage
expect
block
viral
dna
cleavag
packag
lead
accumul
empti
procapsid
unprocess
concatamer
dna
demonstr
naphthylsulphonylamino
phenylpropanamid
bay
ref
bay
target
viral
dna
matur
step
occur
uninfect
eukaryot
cell
target
viral
terminas
attract
strategi
combat
hcmv
infect
addit
bay
two
benzimidazol
ribonucleosid
bdcrb
tcrb
also
shown
inhibit
cleavag
encapsid
viral
dna
amino
acid
mutat
gene
product
identifi
resist
strain
hcmv
maribavir
anoth
benzimidazol
ribonucleosid
addit
switch
l
configur
halogen
posit
benzimidazol
replac
isopropylamin
compound
also
promin
antihcmv
activ
new
antihsv
agent
target
viral
helicaseprimas
complex
thiazolylphenyl
deriv
bil
bay
recent
report
vivo
efficaci
anim
model
infect
compound
seem
function
enhanc
affin
helicaseprimas
complex
hsv
dna
complex
compris
three
viral
protein
hsv
gene
product
fig
togeth
unwind
doublestrand
viral
dna
gener
primer
dna
synthesi
viral
dna
polymeras
antivir
potenc
bay
report
superior
compound
current
use
treat
hsv
infect
data
valid
pursuit
helicaseprimas
inhibitor
treatment
hsv
infect
among
hcmv
human
herpesviru
type
human
herpesviru
type
hcmv
associ
primari
infect
cmv
mononucleosi
congenit
cytomegal
inclus
diseas
well
recurr
infect
pneumon
hepat
retin
enceph
coliti
immunocompromis
host
five
compound
licens
treat
hcmv
infect
ganciclovir
oral
prodrug
valganciclovir
foscarnet
cidofovir
fomivirsen
except
fomivirsen
target
hcmv
immediateearli
mrna
compound
target
viral
dna
polymeras
ganciclovir
must
first
phosphoryl
hcmvencod
protein
kinas
gene
product
fig
also
main
site
mutat
engend
resist
toward
compound
avail
antihcmv
drug
sever
drawback
limit
clinic
util
fomivirsen
must
inject
intraocularli
intravitr
foscarnet
must
given
intraven
three
time
daili
exampl
compound
includ
acyclovir
oral
prodrug
valaciclovir
penciclovir
oral
prodrug
famciclovir
ganciclovir
oral
prodrug
valganciclovir
acycl
nucleosid
analogu
requir
phosphoryl
viral
thymidin
kinas
tk
exert
antivir
activ
hsv
vzv
valaciclovir
famciclovir
protein
kinas
pk
cmv
valganciclovir
maribavir
rapidli
absorb
follow
oral
dose
achiev
mark
reduct
hcmv
titr
semen
primari
infect
gener
occur
patient
year
old
associ
exanthema
subitum
reactiv
later
age
frequent
immunocompromis
individu
particularli
bone
marrow
solidorgan
transplant
recipi
present
standard
antivir
treatment
infect
potent
compound
highest
antivir
select
foscarnet
purin
n
isomer
form
excel
activ
cidofovir
proven
link
diseas
except
possibl
exanthema
subitum
potent
compound
prove
cidofovir
foscarnet
among
epsteinbarr
viru
ebv
respons
infecti
mononucleosi
burkitt
lymphoma
nasopharyng
carcinoma
lymphoprolif
syndrom
opportunist
bcell
lymphoma
oral
hairi
leukoplakia
kaposi
sarcomaassoci
viru
kshv
also
known
associ
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
although
sever
aforement
licens
antiherpet
drug
acyclovir
bvdu
cidofovir
proven
effect
vitro
replic
ebv
case
cidofovir
clinic
manifest
oral
hairi
leukoplakia
none
antivir
drug
licens
treatment
ebv
infect
recent
bdcrb
maribavir
shown
activ
ebv
treatment
infect
associ
diseas
sever
drug
candid
identifi
includ
hpmpa
adenin
cidofovir
ganciclovir
also
inhibit
replic
due
direct
interact
dna
polymeras
yet
establish
whether
compound
effect
replic
cell
cultur
vitro
efficaci
treatment
diseas
vivo
famili
poxvirida
includ
orthopoxvirus
variola
vaccinia
cowpox
monkeypox
camelpox
parapoxvirus
orf
molluscivirus
molluscum
contagiosum
viru
last
natur
case
smallpox
caus
variola
viru
occur
somalia
world
health
organ
declar
smallpox
offici
erad
sinc
known
stock
variola
viru
held
atlanta
usa
center
diseas
control
cdc
koltsovo
russia
state
research
centr
virolog
biotechnolog
vector
illeg
contrast
bdcrb
tcrb
howev
maribavir
seem
target
protein
kinas
gene
product
recent
shown
respons
releas
hcmv
nucleocapsid
nucleu
mean
maribavir
target
stage
viral
life
cycl
follow
viral
dna
matur
packag
preclin
pharmacokinet
toxicolog
studi
maribavir
shown
favour
safeti
profil
excel
oral
bioavail
phase
iii
doseescal
trial
hivinfect
men
asymptomat
hcmv
shed
indic
human
anecdot
report
suggest
topic
intraven
administ
cidofovir
success
treat
recalcitr
molluscum
contagiosum
orf
infect
immunocompromis
patient
cidofovir
licens
clinic
use
treatment
cmv
retin
aid
patient
intraven
inject
howev
could
also
formul
topic
administr
exampl
gel
cream
oral
administr
prodrug
form
deriv
hdpcidofovir
increas
antipoxviru
activ
rel
cidofovir
owe
facilit
cellular
uptak
investig
oral
prodrug
although
ultim
proof
activ
smallpox
human
obviou
reason
provid
discuss
infer
cidofovir
could
effect
therapi
shortterm
prophylaxi
smallpox
relat
poxviru
infect
monkeypox
human
well
treatment
complic
vaccinia
aris
immunocompromis
patient
inadvert
inocul
smallpox
vaccin
vaccinia
murin
model
mimic
progress
dissemin
vaccinia
human
recent
develop
model
athym
nude
mice
inocul
intracutan
vaccinia
viru
system
treatment
cidofovir
dissemin
vaccinia
develop
caus
lesion
heal
regress
anim
treat
way
lesion
complet
almost
complet
disappear
within
day
start
therapi
observ
implic
therapi
complic
smallpox
vaccin
million
peopl
worldwid
chronic
infect
hepadnaviru
hbv
complic
chronic
hepat
b
infect
cirrhosi
hepatocellular
carcinoma
endstag
liver
diseas
account
approxim
million
death
year
drug
formal
approv
treatment
chronic
hepat
b
interferon
ifn
lamivudin
adefovir
dipivoxil
bi
pom
pmea
howev
ifn
treatment
compound
side
effect
influenzalik
symptom
anorexia
depress
requir
dose
adjust
even
discontinu
therapi
contrast
ifn
must
given
parenter
administr
lamivudin
administ
oral
well
toler
lead
resist
patient
one
year
therapi
four
year
therapi
adefovir
dipivoxil
oral
prodrug
adefovir
pmea
intracellular
convers
diphosph
form
act
competit
inhibitor
altern
substrat
hbv
revers
transcriptas
incorpor
dna
act
chain
termin
therebi
prevent
dna
elong
fig
patient
chronic
hbv
infect
either
posit
neg
hepat
b
e
antigen
week
treatment
dose
adefovir
dipivoxil
low
mg
day
result
signific
improv
preserv
stock
variola
viru
ever
use
biolog
andor
terrorist
purpos
highli
mobil
suscept
popul
result
could
catastroph
fact
variola
viru
could
consid
ideal
bioterrorist
weapon
sever
reason
highli
transmiss
aerosol
rout
infect
suscept
person
civilian
popul
countri
contain
high
proport
suscept
unvaccin
person
smallpox
associ
high
morbid
mortal
initi
diagnosi
diseas
seen
year
would
difficult
present
vacciniabas
vaccin
might
effect
first
day
postinfect
formal
approv
drug
treatment
smallpox
first
antivir
compound
use
treatment
prophylaxi
smallpox
treatment
complic
smallpox
vaccin
treatment
eczema
vaccinatum
vaccinia
gangrenosa
methisazon
nmethylisatin
sever
side
effect
report
followup
studi
reveal
methisazon
vitro
activ
monkeypox
viru
variola
viru
concentr
high
ml
therapeut
meaning
yet
sever
potenti
antivir
therapeut
proven
activ
orthopoxviru
infect
cell
cultur
anim
model
concentr
andor
dose
could
use
therapeut
sever
potenti
therapeut
strategi
design
target
cellular
enzym
enzym
includ
inosin
imp
dehydrogenas
respons
convers
imp
xmp
xanthosin
import
step
de
novo
biosynthesi
gtp
sadenosylhomocystein
sah
hydrolas
enzym
respons
hydrolysi
sah
productinhibitor
sadenosylmethionin
sam
depend
methyl
reaction
involv
matur
viral
mrna
oritidin
omp
decarboxylas
enzym
respons
convers
omp
ump
uridin
import
reaction
de
novo
biosynthesi
utp
uridin
cytosin
ctp
synthetas
convert
utp
ctp
viral
enzym
poxvir
dna
polymeras
sever
nucleosid
nucleotid
analogu
identifi
potent
antipoxviru
agent
nucleosid
analogu
includ
wherea
nucleotid
analogu
includ
cidofovir
hpmpdap
hpmpodapi
compound
shown
effect
variou
anim
model
poxviru
infect
cidofovir
protect
mice
lethal
respiratori
infect
either
vaccinia
cowpox
even
administ
singl
system
intraperiton
intranas
aerosol
dose
effect
treatment
vaccinia
viru
infect
sever
combin
immun
defici
scid
mice
form
case
entecavir
would
compet
dgtp
viral
dna
polymeras
intracellular
entecavir
expect
accumul
concentr
inhibitori
wildtyp
hbv
dna
polymeras
like
entecavir
lfmau
proven
potent
inhibitor
dhbv
whv
replic
acut
infect
duck
chronic
infect
woodchuck
respect
highest
dose
administ
mg
kg
day
treatment
lfmau
led
reduct
level
coval
close
circular
whv
dna
concomitantli
longlast
suppress
viraemia
withdraw
therapi
also
lfmau
treatment
follow
therapeut
vaccin
break
immun
toler
advoc
strategi
control
chronic
hbv
infect
human
analogu
lfmau
ldt
ldc
must
also
phosphoryl
form
interact
hbv
dna
polymeras
fact
ldt
ldc
shown
rapidli
extens
phosphoryl
hepatoma
cell
primari
human
hepatocyt
kinas
glycolyt
enzym
use
phosphat
donor
gener
atp
glycolysi
would
import
role
phosphoryl
lnucleosid
diphosph
deriv
noteworthi
adefovir
dipivoxil
drug
approv
worldwid
treatment
chronic
hbv
infect
might
promis
adjunct
therapi
anthrax
human
diseas
caus
pathogen
bacteria
secret
adenylyl
cyclas
toxin
bordetella
pertussi
pseudomona
aeruginosa
yersinia
pesti
inde
activ
cellular
metabolit
adefovir
adefovir
diphosph
pmeadp
recent
shown
inhibit
adenylyl
cyclas
activ
oedema
factor
k
nm
import
virul
factor
pathogenesi
anthrax
especi
earli
stage
bacillu
anthraci
infect
contribut
toxaemia
bacteraemia
picornavirus
includ
enterovirus
polioviru
coxsackievirus
b
echoviru
hepat
viru
rhinovirus
rhinovirus
main
caus
common
cold
wherea
enteroviru
infect
result
myriad
diseas
syndrom
includ
viral
mening
viral
respiratori
infect
virus
polioviru
histor
receiv
attent
success
worldwid
vaccin
campaign
countri
polio
still
remain
endem
niger
nigeria
egypt
india
pakistan
afghanistan
hepat
also
control
suffici
use
kill
viru
vaccin
vaccin
avail
prevent
coxsackievirus
b
echoviru
rhinoviru
infect
compound
extens
studi
enteroand
rhinovirus
pleconaril
histolog
liver
abnorm
well
signific
reduct
serum
hbv
dna
alanin
aminotransferas
concentr
trial
safeti
profil
adefovir
dipivoxil
similar
placebo
hbv
polymeras
mutat
associ
resist
adefovir
identifi
fact
adefovir
dipivoxil
prove
effect
hbvinfect
patient
develop
resist
lamivudin
resist
adefovir
might
eventu
develop
much
slower
rate
lower
frequenc
observ
lamivudin
entecavir
lfmau
uracil
clevudin
ldt
valin
ester
valldc
emtricitabin
ftc
clinic
develop
treatment
chronic
hepat
b
emtricitabin
counterpart
lamivudin
alreadi
licens
treatment
hiv
infect
owe
structur
similar
lamivudin
thought
emtricitabin
might
engend
resist
mutat
substitut
methionin
residu
leucin
valin
residu
seen
lamivudin
therebi
produc
crossresist
lamivudin
entecavir
analogu
vitro
vivo
potenc
seem
greater
lamivudin
patient
chronic
hepat
b
infect
proven
efficaci
dose
low
mg
day
ref
potent
efficaci
also
demonstr
entecavir
woodchuck
hepat
viru
whv
woodchuck
duck
hepat
b
viru
dhbv
duck
entecavir
activ
hepadnaviru
replic
must
nucleosid
analogu
convert
intracellularli
postinfect
lesion
alreadi
appear
untreat
control
anim
mark
protect
effect
develop
viral
myocard
assess
six
day
postinfect
observ
combin
inhibitor
viral
replic
ampligen
immunosuppress
mycophenol
mofetil
could
ideal
treatment
strategi
viral
myocard
implement
treatment
regimen
clinic
set
remain
address
genu
flaviviru
contain
speci
mani
caus
diseas
human
sever
flaviviru
infect
gener
character
enceph
haemorrhag
symptom
mortal
rate
vari
case
central
european
enceph
viru
case
japanes
enceph
viru
tickborn
enceph
viru
previous
known
russian
spring
summer
enceph
viru
import
flavivirus
includ
yellow
fever
viru
dengu
viru
west
nile
viru
st
loui
enceph
viru
murray
valley
enceph
viru
although
fear
possibl
bioterrorist
weapon
develop
tickborn
flavivirus
bioweapon
might
practic
larg
number
infect
tick
would
requir
would
difficult
arrang
infect
readi
feed
deliv
weapon
prospect
therapi
flaviviru
infect
encourag
compound
cyclopentenylcytosin
mpa
pyrazofurin
activ
west
nile
viru
ribavirin
weak
activ
flavivirus
use
ifn
ifn
induc
might
possibl
gener
treatment
start
shortli
infect
benefici
effect
experiment
flaviviru
enceph
model
develop
base
infect
hamster
murin
modoc
viru
acut
phase
infect
associ
flaccid
paralysi
neurolog
sequela
develop
similar
observ
survivor
japanes
enceph
model
suitabl
evalu
antiflaviviru
therapi
present
whether
pegyl
ifn
induc
poli
c
ampligen
offer
greatest
potenti
activ
model
shown
significantli
delay
virusinduc
morbid
paralysi
mortal
due
progress
enceph
relat
model
modoc
viru
scid
mice
noteworthi
ribavirin
provid
benefici
effect
model
whether
given
alon
combin
ifn
arenaviru
speci
known
five
associ
viral
haemorrhag
fever
lassa
junin
machupo
guanarito
sabia
virus
includ
cdc
categori
pathogen
list
gratifi
note
demonstr
tacarib
viru
attenu
junin
viru
strain
vitro
compound
bind
hydrophob
pocket
beneath
canyon
floor
capsid
protein
picornavirus
therebi
freez
viral
capsid
prevent
uncoat
viral
rna
genom
pleconaril
oral
bioavail
achiev
plasma
concentr
greater
requir
inhibit
clinic
rhinoand
enterovir
isol
vitro
addit
central
nervou
system
cn
nasal
secret
drug
present
concentr
sever
fold
higher
plasma
highli
desir
featur
antivir
drug
target
toward
virus
known
caus
cn
upperrespiratorytract
infect
clinic
efficaci
pleconaril
assess
experiment
induc
enteroviru
coxsackieviru
respiratori
infect
adult
volunt
compassion
basi
potenti
lifethreaten
enteroviru
infect
administ
threetim
daili
pleconaril
reduc
durat
sever
picornavirusassoci
viral
respiratori
ill
adolesc
adult
coxsacki
b
virus
thought
main
aetiolog
agent
viral
myocard
common
caus
idiopath
dilat
cardiomyopathi
sever
patholog
condit
often
requir
heart
transplant
therefor
target
chemotherapi
immunosuppress
agent
mycophenol
mofetil
inhibit
develop
coxsacki
virusinduc
myocard
mice
mycophenol
acid
mpa
activ
compon
mycophenol
mofetil
potent
inhibitor
imp
dehydrogenas
antivir
immunosuppress
effect
attribut
interact
reduc
suppli
gtp
fig
therefor
rna
synthesi
benefici
effect
mpa
ascrib
inhibit
viral
replic
titr
infecti
viru
viral
rna
heart
tissu
increas
mycophenolatemofetiltr
anim
compar
untreat
anim
mark
inhibitori
effect
develop
coxsacki
myocard
corrobor
mark
reduct
viru
titr
heart
obtain
ifn
induc
poli
c
poli
c
u
also
known
ampligen
lesser
extent
pegyl
even
start
treatment
poli
c
u
delay
two
day
anim
model
ifn
ifn
induc
also
prove
effect
treatment
experiment
bunyaviru
infect
usual
compound
administ
earli
possibl
infect
flaviviru
infect
ribavirin
use
treatment
togaviru
infect
infect
ifn
whether
pegyl
ifn
induc
ampligen
recommend
therapeut
agent
rhabdovirus
rabi
viru
filovirus
ebola
marburg
virus
among
deadli
virus
infect
human
rabi
almost
invari
fatal
illustr
recent
case
report
howev
rabi
contain
repeat
administr
specif
immunoglobulin
use
kill
rabi
vaccin
soon
possibl
infect
taken
place
vaccin
avail
either
ebola
marburg
infect
virus
classifi
categori
pathogen
filovirus
highli
infecti
airborn
rout
also
transmit
human
direct
contact
viruscontain
bodi
fluid
although
filovirus
could
difficult
potenti
bioterrorist
acquir
biolog
agent
b
anthraci
reput
caus
deadli
diseas
might
make
effort
requir
seem
worthwhil
specif
immunoglobulin
limit
valu
treatment
experiment
ebola
viru
infect
exampl
rhesu
macaqu
treat
day
infect
ebola
zair
viru
experienc
delay
one
day
onset
ill
viraemia
death
antivir
drug
current
clinic
use
includ
ribavirin
provid
protect
filovirus
promis
therapeut
strategi
might
base
use
sah
hydrolas
inhibitor
alreadi
describ
sah
hydrolas
inhibitor
interfer
samdepend
methyl
reaction
fig
involv
cap
viral
mrna
virus
includ
rhabdovirus
vesicular
stomat
viru
vsv
reli
mrna
cap
particularli
sensit
inhibit
sah
hydrolas
inhibitor
biochem
filovirus
similar
rhabdovirus
requir
mrna
therefor
could
logic
deduc
sah
hydrolas
inhibitor
neplanocin
highli
activ
vitro
vivo
vsv
would
also
effect
treatment
ebola
viru
infect
fact
administ
singl
dose
mg
kg
first
second
day
ebola
zair
viru
infect
mice
reduc
peak
viraemia
compar
mocktreat
control
anim
surviv
protect
effect
accompani
probabl
mediat
product
high
arenaviru
replic
suscept
sever
compound
includ
adenosin
analogu
exampl
sah
hydrolas
inhibitor
cytidin
analogu
exampl
cyclopentenyl
cytosin
guanosin
analogu
exampl
impdehydrogenas
inhibitor
ribavirin
sulphat
polysaccharid
exampl
dextran
sulphat
ribavirin
proven
effect
postexposur
prophylaxi
therapi
experiment
arenaviru
infect
anim
model
anecdot
report
suggest
might
also
effect
treatment
arenaviru
infect
machupo
sabia
virus
human
convinc
evid
efficaci
ribavirin
obtain
case
lassa
fever
shown
reduc
casefat
rate
irrespect
time
point
ill
treatment
start
sever
togavirus
bunyavirus
describ
potenti
bioterror
agent
exampl
togavirus
venezuelan
equin
enceph
viru
eastern
equin
enceph
viru
western
equin
enceph
viru
bunyavirus
rift
valley
fever
viru
crimeancongo
haemorrhag
fever
viru
hantavirus
hantaan
viru
howev
hantavirus
unlik
candid
biolog
warfar
purpos
difficult
isol
grow
cell
cultur
transmit
human
evid
infecti
aerosol
crimeancongo
haemorrhag
fever
viru
howev
readili
cultiv
highli
infecti
although
far
evid
infecti
aerosol
form
easili
transmit
human
give
rise
local
epidem
even
nosocomi
infect
casefat
rate
associ
crimeancongo
haemorrhag
viru
higher
viral
haemorrhag
fever
bunyavirus
gener
sensit
ribavirin
also
demonstr
experiment
attract
approach
develop
hcv
inhibitor
target
rnadepend
rna
polymeras
rdrp
impetu
approach
come
fact
vp
ethyl
thio
indol
found
suppress
replic
bovin
viral
diarrhoea
viru
bvdv
inhibitori
effect
rdrp
infect
pestiviru
econom
impact
also
consid
surrog
viru
hcv
compound
identifi
highli
select
inhibitor
bvdv
replic
owe
specif
inhibitori
effect
bvdv
rna
replicas
compound
ref
compound
ref
although
compound
right
could
pursu
treatment
pestiviru
infect
domest
livestock
could
also
model
compound
develop
nonnucleosid
hcv
rdrp
inhibitor
nonnucleosid
rdrp
inhibitor
compound
activ
nanomolar
concentr
seem
first
glanc
much
potent
ribo
nucleosid
analogu
n
hydroxycytidin
report
block
replic
bvdv
hcv
orthomyxovirus
influenza
influenza
b
virus
caus
epidem
human
influenza
virus
isol
wide
varieti
avian
mammalian
speci
caus
widespread
human
epidem
pandem
high
mortal
rate
virus
readili
rapidli
transmit
human
aerosol
rout
wherea
influenza
b
viru
undergo
antigen
drift
base
rel
minor
chang
transit
andor
transvers
mutat
viral
surfac
glycoprotein
haemagglutinin
ha
neuraminidas
na
influenza
viru
prone
antigen
drift
antigen
shift
latter
result
major
antigen
chang
owe
reassort
genom
fragment
influenza
virus
differ
anim
speci
high
virul
influenza
viru
strain
emerg
hong
kong
fact
lethal
influenza
virus
gener
laboratori
revers
genet
accentu
fear
influenza
virus
use
bioterrorist
weapon
addit
highli
pathogen
avian
influenza
virus
exampl
subtyp
respons
fowl
plagu
poultri
transmit
peopl
handl
infect
poultri
transmit
person
person
fatal
cours
pneumonia
associ
acut
respiratori
distress
syndrom
note
individu
infect
avian
viru
mani
year
amantadin
rimantadin
use
prophylaxi
therapi
influenza
viru
infect
gain
wide
accept
three
reason
first
agent
activ
influenza
b
virus
virus
lack
matrix
protein
determin
antiinfluenzaviru
activ
amantadin
rimantadin
second
prospect
rapid
emerg
drugresist
viru
concentr
ebola
virusinfect
mice
hypothes
block
cap
nascent
rna
viral
strand
prevent
dissoci
strand
viral
rna
templat
therebi
lead
accumul
replic
intermedi
replic
intermedi
compos
dsrna
stretch
could
induc
product
high
concentr
ifn
estim
million
peopl
worldwid
infect
hepaciviru
hepat
c
viru
hcv
bloodborn
viru
often
subclin
case
lead
chronic
infect
ultim
result
liver
fibrosi
cirrhosi
hepat
failur
hepatocellular
carcinoma
hcv
infect
common
caus
hepatocellular
carcinoma
main
reason
liver
transplant
among
adult
western
countri
develop
effect
antihcv
therapeut
continu
daunt
challeng
owe
absenc
adequ
anim
model
cellcultur
system
evalu
propag
viru
inhibitor
present
recommend
approv
therapi
chronic
hcv
infect
consist
pegyl
combin
ribavirin
therapi
associ
sustain
viral
respons
rate
among
patient
infect
hcv
genotyp
patient
infect
hcv
anoth
genotyp
treatment
pegyl
ribavirin
individu
genotyp
patient
infect
hcv
genotyp
requir
treatment
week
longer
wherea
patient
infect
hcv
genotyp
treat
week
addit
latter
group
dose
ribavirin
reduc
mg
day
even
mg
day
lower
durat
therapi
combin
pegyl
ribavirin
trivial
issu
owe
cost
therapi
associ
toxic
flulik
syndrom
depress
alter
red
blood
cell
count
although
ifn
gener
immunomodulatori
agent
ribavirin
antivir
agent
two
agent
use
combin
hepat
c
appear
act
way
around
recent
work
focus
develop
compound
interfer
nonstructur
ns
proteinassoci
ntpasehelicas
serin
proteas
rnadepend
rna
polymeras
rna
replicas
activ
hcv
halogen
benzimidazol
benzotriazol
propos
inhibitor
hcv
ntpase
helicas
whether
also
inhibit
hcv
replic
remain
determin
recent
proteas
inhibitor
biln
report
reduc
plasma
concentr
hcv
rna
administ
oral
day
patient
infect
hcv
genotyp
therebi
provid
proofofefficaci
use
hcv
proteas
inhibitor
human
hmpv
first
isol
young
children
respiratorytract
diseas
clinic
symptom
similar
caus
rsv
rang
upperrespiratorytract
diseas
sever
bronchiol
pneumonia
hmpv
similar
rsv
infect
usual
occur
winter
month
common
young
children
elderli
peopl
immunocompromis
individu
studi
carri
hospit
patient
respiratorytract
ill
hmpv
secondmostdetect
viral
pathogen
rsv
first
two
success
winter
season
specif
antivir
treatment
hmpv
infect
signific
number
patient
diagnos
influenzalik
ill
harbour
rsv
influenza
rsv
infect
occur
approxim
time
need
distinguish
two
prescrib
specif
antivir
treatment
mention
specif
treatment
influenza
consist
na
inhibitor
zanamivir
oseltamivir
wherea
rsv
infect
approv
therapi
aerosol
administr
ribavirin
practic
howev
ribavirin
rare
use
owe
technic
burden
deliveri
aerosol
inhal
attempt
made
develop
rsv
inhibitor
target
viral
fusion
f
protein
therefor
block
viruscel
fusion
syncytium
format
exampl
biscarbamoylmethylsulphamoyl
phenylamino
acid
prove
efficaci
administ
prophylact
hour
postinfect
intranas
rout
mice
cotton
rat
african
green
monkey
intranas
infect
rsv
past
human
coronaviru
infect
infect
viru
consid
suffici
seriou
control
either
vaccin
mutant
third
possibl
side
effect
affect
cn
particularli
document
amantadin
given
specif
influenza
viru
strain
alreadi
circul
influenza
vaccin
like
limit
valu
newli
emerg
influenza
strain
whether
occur
natur
bioterrorist
weapon
case
antivir
drug
direct
function
share
mani
influenza
strain
possibl
would
constitut
best
line
defenc
na
inhibitor
zanamivir
oseltamivir
meet
requir
compound
prevent
remov
sialic
acid
nacetylneuramin
acid
residu
glycopeptid
receptor
fig
viral
na
would
otherwis
allow
viru
particl
releas
infect
cell
spread
neighbour
cell
licens
treatment
prophylaxi
influenza
viru
infect
would
advis
stockpil
compound
particularli
oseltamivir
conveni
administ
capsul
use
case
influenza
viru
outbreak
attack
paramyxovirus
includ
parainfluenza
sendai
viru
mump
viru
measl
viru
hendra
nipah
virus
pneumovirus
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
parainfluenza
littl
studi
either
prevent
cur
viewpoint
mump
measl
like
rubella
suffici
contain
vaccin
make
nipah
viru
relat
hendra
viru
rsv
hmpv
paramyxovirus
antivir
approach
requir
nipah
viru
isol
outbreak
viral
enceph
malaysia
year
ago
mani
characterist
would
make
potenti
bioterrorist
weapon
specif
antivir
treatment
nipah
viru
infect
activ
albeit
low
level
ec
select
index
sarscov
replic
cell
cultur
addit
n
hydroxycytidin
calpain
inhibitor
n
lvalyllleucin
inhibit
sarscov
replic
ec
select
index
target
calpain
inhibitor
remain
elucid
inhibitori
effect
sarscov
select
index
ec
valu
low
ml
observ
varieti
compound
includ
vancomycin
eremomycin
teicoplanin
aglycon
deriv
mannosespecif
plant
lectin
deriv
galanthu
nivali
snowdrop
hippeastrum
hybrid
amarylli
allium
porrum
leek
might
owe
antivir
activ
interact
compon
viral
entri
machineri
glycyrrhizin
also
shown
inhibit
replic
sarscov
concentr
ec
ml
could
achiev
target
tissu
organ
effect
agent
least
prophylaxi
earli
postexposur
manag
sar
would
seem
human
ifn
either
pegyl
recent
shown
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
attend
pulmonari
damag
cynomolgu
macaqu
infect
experiment
sarscov
preliminari
result
warrant
studi
pegyl
commerci
avail
prophylact
earli
postexposur
treatment
sar
reemerg
rotaviru
associ
worldwid
epidem
viral
gastrointestin
infect
clinic
import
reovirus
although
sever
attempt
still
made
develop
effect
vaccin
rotaviru
infect
current
treatment
infecti
diarrhoea
mainli
base
administr
fluid
physiolog
salin
prevent
dehydr
yet
point
sah
hydrolas
inhibitor
see
offer
great
promis
treatment
reo
rota
viru
infect
cell
cultur
found
inhibit
rotaviru
replic
ec
ml
select
index
sinc
identif
hiv
caus
agent
aid
year
ago
mani
effort
made
keep
diseas
control
compound
formal
approv
antihiv
drug
use
varieti
combin
divid
five
categori
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
didanosin
zalcitabin
stavudin
lamivudin
abacavir
emtricitabin
nucleotid
revers
transcriptas
inhibitor
ntrti
tenofovir
disoproxil
fumar
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
delavirdin
efavirenz
proteas
inhibitor
pi
specif
antivir
therapi
chang
markedli
emerg
sever
acut
respiratori
syndrom
sar
unequivoc
associ
newli
discov
coronaviru
sarsassoci
coronaviru
sarscov
diseas
mainli
character
influenzalik
symptom
high
fever
myalgia
dyspnea
lymphopoenia
lung
infiltr
pneumonia
lead
acut
breath
problem
overal
mortal
rate
elderli
high
genom
structur
life
cycl
phylogenet
relationship
sarscov
address
previous
sever
protein
encod
sarscov
genom
could
consid
target
chemotherapeut
intervent
spike
protein
coronaviru
main
proteinas
ntpasehelicas
rnadepend
rna
polymeras
possibl
viralproteinmedi
process
coronaviru
protein
mediat
infect
permiss
cell
interact
domain
angiotensinconvert
enzym
function
receptor
sarscov
fragment
protein
correspond
residu
bind
effici
full
domain
fact
fragment
block
sproteinmedi
infect
ic
nm
ic
full
domain
nm
also
human
monoclon
antibodi
protein
block
associ
sarscov
indic
site
could
target
drug
develop
first
smallmolecularweight
inhibitor
found
interact
activ
catalyt
site
ethylamino
acid
alreadi
describ
whether
inhibit
sarscov
infect
remain
ascertain
coronaviru
main
proteinas
mpro
also
known
target
design
antisarscov
drug
propos
compound
proven
activ
rhinoviru
proteinas
could
modifi
make
activ
coronavirus
first
modif
remov
methylen
group
pfluorophenylalanin
residu
creat
model
structur
sarscov
protein
work
area
could
advanc
structurebas
drug
design
sar
anoth
potenti
target
develop
antisar
agent
sarscovassoci
ntpasehelicas
sarscov
rnadepend
rna
polymeras
also
potenti
target
antisar
therapi
enzym
contain
hydrophob
pocket
nonnucleosid
inhibitor
proven
activ
hcv
polymeras
revers
transcriptas
mani
nucleosid
analogu
expect
target
sarscov
rna
polymeras
efficaci
determin
n
hydroxycytidin
incident
compound
accredit
antihcv
activ
show
sever
noteworthi
compound
proceed
clinic
trial
includ
follow
compound
bicyclam
ref
specif
target
coreceptor
use
tlymphotrop
hiv
strain
enter
cell
schc
sch
specif
target
coreceptor
use
macrophag
tropic
hiv
strain
enter
cell
new
nrti
market
reverset
tm
amdoxovir
also
known
dapd
dioxolan
activ
hiv
isol
resist
nrti
zidovudin
lamivudin
new
nnrti
capravirin
etravirin
effect
strain
carri
mutat
make
resist
classic
nnrti
nevirapin
efavirenz
diketoacid
deriv
target
integrasemedi
strandtransf
reaction
first
integras
inhibitor
reach
clinic
studi
final
tipranavir
first
nonpeptidomimet
inhibitor
hiv
proteas
brought
clinic
expect
retain
activ
isol
develop
resist
classic
peptidomimet
pi
sever
therapeut
strategi
still
preclin
stage
pursu
chemotherapi
hiv
infect
includ
follow
strategi
downmodul
main
cellular
receptor
use
hiv
bind
target
cell
cyclotriazadisulphonamid
cada
use
compound
specif
bind
viral
envelop
glycoprotein
r
methylpiperazin
therebi
block
interact
use
plant
lectin
deriv
snowdrop
agglutinin
gna
amarylli
lectin
hha
aglycon
glycopeptid
antibiot
vancomycin
teicoplanin
eremomycin
specif
interact
develop
pyranodipyrimidin
inhibitor
hiv
integras
inhibit
integr
manner
differ
diketoacid
deriv
show
crossresist
diketoacid
deriv
final
two
new
class
compound
naminoimidazol
deriv
naim
pyridin
oxid
deriv
seem
inhibit
postintegr
transcript
transactiv
event
exact
natur
remain
elucid
recent
new
class
antihiv
compound
call
matur
inhibitor
identifi
betulin
acid
disrupt
late
step
gag
process
involv
convers
capsid
precursor
matur
capsid
protein
virion
releas
cultur
longer
infecti
resist
mutat
identifi
cleavag
site
studi
requir
assess
whether
similar
compound
therapeut
potenti
hiv
infect
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
atazanavir
enfuvirtid
fusion
inhibitor
fi
addit
variou
new
antihiv
agent
describ
present
clinic
preclin
develop
new
agent
target
either
viral
protein
old
one
revers
transcriptas
proteas
envelop
glycoprotein
mediat
fusion
new
yet
therapeut
valid
viral
process
viral
adsorpt
mediat
glycoprotein
coreceptor
usag
provir
dna
integr
transcript
transactiv
fig
treatment
hcv
rna
viru
exampl
arenaand
bunyaviru
infect
sah
hydrolas
treatment
rna
viru
infect
ebola
marburg
viru
rna
viru
infect
rotaviru
rnadepend
rna
polymeras
treatment
rna
viru
flaviviru
hepaciviru
infect
final
ifn
seem
good
therapeut
agent
viral
infect
like
caus
coxsackievirus
hepat
b
c
virus
sarscov
yet
suffici
curb
therapeut
prophylact
approach
present
chemic
plu
pegyl
unpegyl
form
formal
approv
treatment
viral
infect
least
half
intend
treat
hiv
infect
similar
number
compound
also
preclin
clinic
develop
least
half
expect
reach
antivir
drug
market
overal
antivir
strategi
seem
target
inhibit
viral
dna
polymeras
treatment
dna
viru
infect
helicasentpas
treatment
hsv
hcv
sarscov
infect
imp
dehydrogenas
